← back to search

Michael A.S. Jewett

Princess Margaret Cancer Centre · CA
Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Testicular diseases and treatments, and Renal and related cancers.
h-index
86
citations
26,042
works
622
NIH funding
primary concept
Medicine
email

Recent publications

A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types
European Urology 2025cited by 10position: middledoi
'BJUI Clinical Dilemma': the incidental small renal mass in a solitary kidney.
2025cited by 1position: contributordoi
What is required to deliver practice-changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study.
2025cited by 1position: contributordoi
Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
2024cited by 8position: contributordoi
Primary retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumours: outcomes and adjuvant chemotherapy.
2024cited by 5position: contributordoi
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
The Lancet Oncology 2023cited by 241position: middledoi
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy
British Journal of Urology 2023cited by 59position: middledoi
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
2023cited by 53position: contributordoi
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.
2022cited by 15position: contributordoi
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma
European Urology 2021cited by 66position: middledoi
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement
Cancer 2021cited by 44position: middledoi
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients
Urologic Oncology Seminars and Original Investigations 2021cited by 39position: middledoi
Cytoreductive nephrectomy and exposure to sunitinib – a <i>post hoc</i> analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial
British Journal of Urology 2021cited by 23position: middledoi
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†
European Urology 2020cited by 88position: middledoi
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
2020cited by 9position: contributordoi
Abstract B23: <i>FGFR3</i> mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
Clinical Cancer Research 2020cited by 0position: middledoi
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation
Journal of Clinical Oncology 2019cited by 153position: middledoi
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Annals of Oncology 2018cited by 325position: middledoi
Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer
Urologic Oncology Seminars and Original Investigations 2018cited by 33position: middledoi
The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non‐muscle‐invasive bladder cancer
British Journal of Urology 2018cited by 31position: middledoi
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
The Lancet 2016cited by 635position: middledoi
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
Annals of Oncology 2016cited by 60position: middledoi
Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell–Cell Communication in Renal Cell Carcinoma
European Urology Focus 2015cited by 151position: middledoi
Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma
American Journal Of Pathology 2015cited by 63position: middledoi
Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.
Journal of Clinical Oncology 2015cited by 54position: middledoi
Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma
Clinical & Experimental Metastasis 2015cited by 24position: middledoi
Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma
Molecular Cancer 2014cited by 196position: middledoi
miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma
Journal of Molecular Diagnostics 2014cited by 64position: middledoi
Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer
Journal of Clinical Oncology 2013cited by 134position: middledoi
Rationale for Percutaneous Biopsy and Histologic Characterisation of Renal Tumours
European Urology 2012cited by 246position: middledoi

Grants

Collaborative Research: Cell-free glycoprotein synthesis technology for point-of-care vaccine biomanufacturing
NSF2341123$219,0672023–2026PIRePORTER
Collaborative Research: Cell-free glycoprotein synthesis technology for point-of-care vaccine biomanufacturing
NSF1936789$390,3432020–2023PIRePORTER
Cell-Free Systems Conference
NSF1937811$26,6202019–2020PIRePORTER
Collaborative Research: Repurposing the translation apparatus for mirror image polypeptide synthesis
NSF1716766$475,0002017–2021PIRePORTER
Synthetic Biology, Engineering, Evolution & Design 2016 (SEED 2016), Chicago, IL, July 18-21, 2016
NSF1634295$25,0002016–2016PIRePORTER
Collaborative Research: Glycoengineering Without Borders: Bacterial Cell-Free Glycoprotein Synthesis
NSF1413563$300,0002014–2018PIRePORTER
Materials World Network: Chemical and BIological Approaches to Sequence Controlled Polymers
NSF1108350$372,0002011–2016PIRePORTER
Collaborative Research: Engineering Genetically Augmented Polymers (GAPS)
NSF0943393$637,3512009–2014PIRePORTER
International Research Fellowship Program: Systems Biology of Glucose Repression in Yeast for Metabolic Engineering
NSF0504168$128,4162005–2007PIRePORTER

Frequent collaborators

· 7 papers (2020–2025)Robert G. Uzzo · Case Comprehensive Cancer Center6 papers (2012–2022)George M. Yousef · Hospital for Sick Children5 papers (2012–2015)Theodorus van der Kwast · Collaborative Group (United States)5 papers (2012–2024)Christopher G. Wood · Massachusetts Eye and Ear Infirmary4 papers (2015–2021)Christopher J. Kane · University of San Diego4 papers (2015–2021)Keith T. Flaherty · Boston Medical Center4 papers (2015–2021)Manal Gabril · Dalhousie University4 papers (2012–2015)Janice P. Dutcher · New York Medical College4 papers (2015–2021)Judith Manola · Dana-Farber Cancer Institute4 papers (2015–2021)Naomi B. Haas · Samsung Medical Center4 papers (2015–2021)Andreas Scorilas · National and Kapodistrian University of Athens4 papers (2014–2015)Heba Khella · Queen's University4 papers (2012–2015)Robert S. DiPaola · University of Kentucky4 papers (2015–2021)Alexandre R. Zlotta · Collaborative Group (United States)4 papers (2012–2020)Sergey N. Krylov · York University3 papers (2014–2015)Andrew Evans · Royal Derby Hospital3 papers (2012–2014)Wolfgang Otto · University of Regensburg3 papers (2018–2020)Arndt Hartmann · Methodist University3 papers (2018–2020)Michael B. Atkins · Georgetown University3 papers (2015–2022)